Cargando…

Clinical pharmacodynamic factors in docetaxel toxicity

Neutropenia is the main dose-limiting toxicity occurring in docetaxel treatment. The objective of this study was to identify pharmacodynamic (PD) factors responsible for the neutropaenia caused by docetaxel. Data were obtained from 92 patients treated with docetaxel as a monochemotherapy in two diff...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puisset, F, Alexandre, J, Treluyer, J-M, Raoul, V, Roché, H, Goldwasser, F, Chatelut, E
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2007
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360335/ https://www.ncbi.nlm.nih.gov/pubmed/17595656 http://dx.doi.org/10.1038/sj.bjc.6603872

Ejemplares similares

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
por: Bousquet, G, et al.
Publicado: (2011)

Low immunogenicity of seasonal trivalent influenza vaccine among patients receiving docetaxel for a solid tumour: results of a prospective pilot study
por: Loulergue, P, et al.
Publicado: (2011)

Docetaxel-based induction therapy prior to radiotherapy with or without docetaxel for non-small-cell lung cancer
por: Scagliotti, G V, et al.
Publicado: (2006)

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
por: Rouits, E, et al.
Publicado: (2008)

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
por: Tebbutt, N C, et al.
Publicado: (2013)

SCOTROC 2A: Carboplatin followed by docetaxel or docetaxel–gemcitabine as first-line chemotherapy for ovarian cancer
por: Vasey, P A, et al.
Publicado: (2006)

SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer
por: Clamp, A R, et al.
Publicado: (2006)

Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients
por: Huillard, O, et al.
Publicado: (2013)

Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial
por: Engebraaten, Olav, et al.
Publicado: (2012)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
por: Duran, I, et al.
Publicado: (2006)

A randomised multicentre phase II study with cisplatin/docetaxel vs oxaliplatin/docetaxel as first-line therapy in patients with advanced or metastatic non-small cell lung cancer
por: Atmaca, A, et al.
Publicado: (2013)

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
por: Petrioli, R, et al.
Publicado: (2011)

Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2006)

Personalising docetaxel and G-CSF schedules in cancer patients by a clinically validated computational model
por: Vainas, O, et al.
Publicado: (2012)

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours
por: Delord, J P, et al.
Publicado: (2005)

A randomised phase II trial of preoperative chemotherapy of cisplatin–docetaxel or docetaxel alone for clinical stage IB/II non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG 0204)
por: Kunitoh, H, et al.
Publicado: (2008)

Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer
por: Oh, S C, et al.
Publicado: (2005)

Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer
por: Gamucci, T, et al.
Publicado: (2007)

Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer
por: Yamaguchi, K, et al.
Publicado: (2006)

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours
por: Razak, A R A, et al.
Publicado: (2011)

Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer
por: Mathew, P, et al.
Publicado: (2008)

Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer
por: Day, F L, et al.
Publicado: (2011)

Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents
por: Chatelut, E, et al.
Publicado: (2012)

RPN2 expression predicts response to docetaxel in oesophageal squamous cell carcinoma
por: Kurashige, J, et al.
Publicado: (2012)

Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
por: Le Louedec, Félicien, et al.
Publicado: (2020)

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
por: Martin, L P, et al.
Publicado: (2012)

Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer
por: Mellado, B, et al.
Publicado: (2009)

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
por: Ciardiello, F, et al.
Publicado: (2006)

Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2008)

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
por: Vasey, P A, et al.
Publicado: (2008)

Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancer
por: Chiarion-Sileni, V, et al.
Publicado: (2007)

Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
por: Paz-Ares, L, et al.
Publicado: (2008)

Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study
por: Katsumata, N, et al.
Publicado: (2005)

Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study
por: Roy, A, et al.
Publicado: (2012)

A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
por: Allegrini, G, et al.
Publicado: (2008)

Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open‐source R package mapbayr
por: Le Louedec, Félicien, et al.
Publicado: (2021)

Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor
por: Michael, M, et al.
Publicado: (2010)

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours
por: Eskens, F A L M, et al.
Publicado: (2014)

Treatment with docetaxel and cisplatin in advanced adrenocortical carcinoma, a phase II study
por: Urup, T, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_hv51llas2e7153s3pme1ug2opq